Archives

  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2018-07

    • Lipo3K Transfection Reagent: High-Efficiency, Low-Toxicit...

    2026-01-12

    Lipo3K Transfection Reagent: High-Efficiency, Low-Toxicity Lipid Transfection for Challenging Cells

    Executive Summary. Lipo3K Transfection Reagent is a cationic lipid-based reagent optimized for high-efficiency delivery of DNA, siRNA, and mRNA into a wide range of cell types, including hard-to-transfect models (APExBIO). It demonstrates 2–10-fold higher transfection efficiency than Lipo2K under controlled conditions, while maintaining significantly reduced cytotoxicity, thus allowing direct cell harvest for downstream assays within 24–48 hours post-transfection (Khalaila & Skorecki, 2025). The formulation includes a proprietary nuclear delivery enhancer (Lipo3K-A) that further boosts plasmid DNA transfection, with optimal performance in serum-containing media and no medium change required. Lipo3K has been benchmarked against Lipofectamine® 3000 and is compatible with both single and co-transfection workflows, supporting gene expression and RNA interference (RNAi) research. The kit is stable for one year at 4°C and ships as ready-to-use components.

    Biological Rationale

    Efficient transfection of nucleic acids is foundational for gene expression studies, functional genomics, and RNAi workflows. Many cell lines, including primary and suspension cells, exhibit low uptake of naked DNA or RNA due to plasma membrane barriers and endosomal sequestration (Khalaila & Skorecki, 2025). Cationic lipid transfection reagents, such as Lipo3K, form electrostatic complexes with nucleic acids, promoting cellular uptake via endocytosis and facilitating cytoplasmic release (internal). The advancement of lipid-based delivery has paralleled the need to dissect gene function in disease models, particularly where robust and reproducible gene transfer is essential for experimental validity. Lipo3K was developed to address the limitations of older reagents, including low efficiency in refractory cells and cytotoxic effects that confound downstream analysis (internal).

    Mechanism of Action of Lipo3K Transfection Reagent

    Lipo3K is composed of cationic lipids and a proprietary transfection enhancer (Lipo3K-A). Upon mixing with nucleic acids, Lipo3K-B forms nanoscale lipid-nucleic acid complexes through electrostatic interaction. These complexes are internalized by cells via endocytosis. Lipo3K-A enhances the nuclear entry of plasmid DNA, likely by modulating endosomal escape and nuclear import pathways, although the exact mechanism remains under investigation (Khalaila & Skorecki, 2025). For siRNA transfection, only Lipo3K-B is required, as nuclear localization is not necessary for RNA interference. The reagent is compatible with serum and antibiotics, but optimal results are obtained in serum-containing, antibiotic-free media. Cellular uptake is rapid, and gene expression or knockdown is typically detectable within 24–48 hours, depending on the nucleic acid payload. The low cytotoxicity profile allows direct cell lysis or harvesting post-transfection, eliminating the need for media exchange and reducing workflow complexity (APExBIO).

    Evidence & Benchmarks

    • Lipo3K achieves 2–10× higher transfection efficiency compared to Lipo2K in HEK293, HeLa, and primary cell models (manufacturer data, APExBIO).
    • Cytotoxicity levels are significantly reduced versus Lipofectamine® 3000, as measured by viability assays at 24 and 48 hours post-transfection (Figure 4, Khalaila & Skorecki, 2025).
    • The nuclear delivery enhancer (Lipo3K-A) improves plasmid DNA transfection rates up to 3× in difficult-to-transfect cells, as demonstrated in side-by-side experiments (Table 2, internal).
    • Lipo3K supports co-transfection of plasmids and siRNAs with no cross-inhibition, enabling multiplexed gene expression and knockdown studies (internal).
    • The dual-component system is stable at 4°C for at least 12 months, with no loss of efficiency after repeated use (product stability sheet, APExBIO).

    Applications, Limits & Misconceptions

    Lipo3K Transfection Reagent is validated for gene expression studies, RNA interference research, and co-transfection protocols in both adherent and suspension cultures. It is particularly effective for difficult-to-transfect cell lines, such as primary neurons, hematopoietic cells, and stem cells (Khalaila & Skorecki, 2025). The reagent is suitable for high-throughput screening, CRISPR/Cas9 delivery, and multiplexed gene modulation workflows.

    Common Pitfalls or Misconceptions

    • Lipo3K is not suitable for in vivo systemic delivery; it is designed for in vitro cell culture applications only.
    • The nuclear delivery enhancer (Lipo3K-A) is required only for plasmid DNA, not siRNA, and using it with siRNA confers no additional benefit.
    • Although compatible with antibiotics, using antibiotic-free media during transfection maximizes efficiency.
    • Overloading with nucleic acid (>1 μg/well in 24-well plates) may increase cytotoxicity and reduce transfection efficiency.
    • Lipo3K does not bypass the need for optimization in highly sensitive or unique cell types; empirical titration is still recommended for best results.

    Workflow Integration & Parameters

    Lipo3K Transfection Reagent is supplied as a two-component system (Lipo3K-A and Lipo3K-B) in the K2705 kit. For DNA transfection, mix Lipo3K-B with nucleic acid in serum-free medium, incubate for 5–10 minutes at room temperature, then add Lipo3K-A. The complexes are then added directly to cells in serum-containing media. For siRNA transfection, only Lipo3K-B is required. No medium change is needed post-transfection, and cells can be harvested as early as 24 hours. The reagent is compatible with most standard cell culture plastics and workflows. The components must be stored at 4°C and are stable for up to one year. APExBIO provides detailed protocols for both single and co-transfection setups (Lipo3K Transfection Reagent).

    For more comprehensive experimental design and troubleshooting guidance, see Mechanistic Innovation and Translational Impact: Reimagining Difficult Cell Transfection Workflows, which focuses on the application of Lipo3K in drug resistance modeling—a context this article extends by providing updated benchmarks and workflow integration advice. For mechanistic insights into overcoming cellular barriers, see Redefining Nucleic Acid Delivery, which this article clarifies by mapping the specific contributions of the Lipo3K-A enhancer in nuclear delivery.

    Conclusion & Outlook

    Lipo3K Transfection Reagent, developed by APExBIO, provides an advanced platform for high efficiency, low-toxicity lipid transfection of nucleic acids into diverse cell types. Its robust performance, compatibility with multiplexed workflows, and ease of use position it as a preferred choice for demanding gene expression and RNAi studies. Ongoing research continues to refine its mechanism of action and expand its validated applications. For detailed specifications and ordering information, visit the Lipo3K Transfection Reagent product page.